What is the standard postpartum prophylactic dose of anti‑D immune globulin (Rho(D) Ig) for an unsensitized Rh‑negative mother after delivery of an Rh‑positive infant?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 20, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Standard Postpartum Anti-D Dose

Administer 300 μg (1500 IU) of anti-D immune globulin intramuscularly within 72 hours of delivery to an unsensitized Rh-negative mother who delivers an Rh-positive infant. 1, 2

Dosing Protocol

The standard postpartum dose is:

  • 300 μg (1500 IU) administered intramuscularly, preferably in the deltoid muscle 2
  • Timing: Within 72 hours of delivery for optimal effectiveness 1, 2
  • Never administer intravenously when using IM preparations 2
  • Never administer to the neonate 2

Critical Timing Considerations

While 72 hours is the target window, delayed administration still provides benefit:

  • Anti-D may still be given beyond 72 hours if the window is missed, as some protection is better than none 1, 2
  • Administration up to 28 days postpartum is still recommended when the 72-hour window is missed 1
  • The degree of protection decreases with delayed administration, but it remains preferable to no administration at all 1

Dose Modification for Large Fetomaternal Hemorrhage

One standard 300 μg dose covers up to 15 mL of fetal red blood cells (approximately 30 mL of fetal whole blood). 2, 3

When excessive fetomaternal hemorrhage is suspected:

  • Perform quantitative testing (modified Kleihauer-Betke or flow cytometry) to determine the volume of fetal red cells in maternal circulation 2, 4
  • Calculate additional doses: Divide the volume of fetal RBCs by 15 mL to determine the number of vials needed 2
  • If the calculation results in a fraction, round up to the next whole number (e.g., if 1.4, give 2 vials) 2
  • Additional dosing formula: Give 10 μg of anti-D for every additional 0.5 mL of fetal red blood cells beyond the initial 15 mL 1, 3

When to Suspect Large Fetomaternal Hemorrhage

Consider quantitative testing in these high-risk scenarios:

  • Placental abruption 3
  • Blunt abdominal trauma 3
  • Manual removal of placenta 3
  • Cesarean delivery 3
  • Stillbirth 3

Special Circumstance: Recent Antenatal Dose

If delivery occurs within 3 weeks of the 28-week antenatal dose, the postpartum dose may be withheld unless there is evidence of fetomaternal hemorrhage exceeding 15 mL of red blood cells. 2 This recognizes that adequate anti-D levels may still be present from the recent antenatal administration.

Common Pitfalls to Avoid

  • Do not skip postpartum anti-D even if the mother received antenatal prophylaxis at 28 weeks—both doses are required for optimal protection (reducing alloimmunization from 1.8% to 0.1-0.2%) 1
  • Do not assume a standard dose is sufficient after traumatic delivery, cesarean section, or placental complications—always consider testing for excessive fetomaternal hemorrhage 3, 4
  • Do not delay administration waiting for laboratory confirmation of infant blood type if it will exceed 72 hours—give anti-D empirically and it can be documented as unnecessary later if the infant is Rh-negative 1
  • Do not confuse IM and IV preparations—verify the route specified on the product label, as IM products must never be given IV 2

Clinical Effectiveness

This two-dose protocol (28 weeks antenatal + postpartum) is highly effective:

  • Postpartum anti-D alone reduces alloimmunization from 13-17% to 1-2% 1
  • Adding the antenatal dose further reduces alloimmunization from 1.8% to 0.1-0.2% 1

References

Guideline

Management Guidelines for Rh Negative Pregnancy

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Prevention of Rh alloimmunization.

Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC, 2003

Research

Postpartum Rh immunoprophylaxis.

Obstetrics and gynecology, 2012

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.